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Abstract
Background: Varenicline was approved for use in the United States in 2006, and has proven to be the most
effective smoking cessation therapy currently available. Unfortunately, there have been some recent concerns
regarding its safety. The FDA added a black box warning to varenicline in July, 2009, advising patients and
providers of the possible link between varenicline and suicidal ideation and/or behaviors. The addition of the
black box warning to varenicline has lead to several studies to investigate whether or not there is a causal
relationship.
Method: An exhaustive search of the available medical literature was performed using MEDLINE, Web of
Science, PubMed, CINAHL, Evidence-Based Medicine Reviews Multifile, PsycINFO, and International
Pharmaceutical Abstracts, using the keywords “varenicline”, “suicide”, and “depression”.
Results: Four studies were identified and included in this review, including one randomized control trial, two
observational cohorts, and one open-label trial. In the RCT, there were no cases of suicidal behaviors, and a
minimal increase in depressed mood and mood disturbances when compared to placebo. One cohort showed
a minimal risk increase of fatal and non-fatal self harm when compared to nicotine replacement therapy
(NRT), and an increased risk of suicidal ideation. In the second cohort, there were four cases of attempted
suicide and two cases of suicidal ideations. One percent of the study group reported depressed mood, and less
than one percent reported mood change. The open-label trial reported no increase in scores related to
suicidality, and a reduction in mood changes and depression.
Conclusion: This review used the GRADE analysis for each study, and the outcomes analyzed were
depression, suicidal ideations/behaviors, and fatal and non-fatal self harm. The overall GRADE of the
evidence was very low. But varenicline has still proven to be the most effective form of smoking cessation
available to date. And while there may be a minimal increased risk of suicide with its usage, the risk of
eventually dying from smoking related illness for smokers is 50%. There needs to be further studies conducted
on patients who are at an increased risk of suicide, mainly those with depression and/or other psychiatric
illnesses, to see if the use of the drug is safe in these populations. Providers should continue to prescribe its
use in these populations with caution. But for the general public, it appears to be a safe and effective means of
smoking cessation.
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ABSTRACT 
 
Background:  Varenicline was approved for use in the United States in 2006, 
and has proven to be the most effective smoking cessation therapy currently 
available.  Unfortunately, there have been some recent concerns regarding its 
safety.  The FDA added a black box warning to varenicline in July, 2009, advising 
patients and providers of the possible link between varenicline and suicidal 
ideation and/or behaviors.  The addition of the black box warning to varenicline 
has lead to several studies to investigate whether or not there is a causal 
relationship.    
 
Method:  An exhaustive search of the available medical literature was performed 
using MEDLINE, Web of Science, PubMed, CINAHL, Evidence-Based Medicine 
Reviews Multifile, PsycINFO, and International Pharmaceutical Abstracts, using 
the keywords “varenicline”, “suicide”, and “depression”.   
 
Results:  Four studies were identified and included in this review, including one 
randomized control trial, two observational cohorts, and one open-label trial.  In 
the RCT, there were no cases of suicidal behaviors, and a minimal increase in 
depressed mood and mood disturbances when compared to placebo.  One 
cohort showed a minimal risk increase of fatal and non-fatal self harm when 
compared to nicotine replacement therapy (NRT), and an increased risk of 
suicidal ideation.  In the second cohort, there were four cases of attempted 
suicide and two cases of suicidal ideations.  One percent of the study group 
reported depressed mood, and less than one percent reported mood change.   
The open-label trial reported no increase in scores related to suicidality, and a 
reduction in mood changes and depression. 
 
Conclusion:  This review used the GRADE analysis for each study, and the 
outcomes analyzed were depression, suicidal ideations/behaviors, and fatal and 
non-fatal self harm. The overall GRADE of the evidence was very low.  But 
varenicline has still proven to be the most effective form of smoking cessation 
available to date.  And while there may be a minimal increased risk of suicide 
with its usage, the risk of eventually dying from smoking related illness for 
smokers is 50%.  There needs to be further studies conducted on patients who 
are at an increased risk of suicide, mainly those with depression and/or other 
psychiatric illnesses, to see if the use of the drug is safe in these populations.  
Providers should continue to prescribe its use in these populations with caution.  
But for the general public, it appears to be a safe and effective means of smoking 
cessation. 
 
Keywords:  Varenicline, suicide, suicidal ideation, suicidal behaviors, depression 
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INTRODUCTION 
Background 
Cigarette smoking continues to be a world-wide health problem, and is the 
leading preventable cause of death in the U.S., causing approximately 443,000 
deaths in the U.S. annually (Centers for Disease Control and Prevention, 2008).    
Approximately 50% of smokers will eventually die from a tobacco related cause, 
including, but not limited to, coronary artery disease, cancer, chronic obstructive 
pulmonary disease, stroke, peripheral vascular disease, and aortic aneurysms.   
Smoking cessation programs, therapies, and preventions continue to be 
designed and evaluated by both government and private agencies due to the 
numerous smoking related health issues. 
Varenicline, the newest smoking cessation therapy, was introduced by 
Pfizer and approved by the Food and Drug Administration (FDA) for use in the 
United States in 2006.  It is the third product approved by the FDA for smoking 
cessation, the other two being nicotine replacement therapy (NRT) and 
bupropion (Cahill, Stead, & Lancaster, 2009).   Varenicline’s mechanism of action 
differs from both NRT and bupropion, acting as a partial agonist of the 
alpha4beta2 acetylcholine receptors in the brain and nervous system, which 
causes a subsequent release of dopamine (Jiménez-Ruiz, Berlin, & Hering, 
2009).  This replicates the effect that nicotine has on the brain.  It is thought that 
varenicline assists in smoking cessation by decreasing the symptoms of tobacco 
withdrawal, which include irritability, mood changes, anxiety, insomnia, 
restlessness and weight gain.  Additionally, varenicline has an affinity for the 
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alpha4beta2 receptors that is 15 times stronger than that of nicotine (Kasliwal, 
Wilton, & Shakir, 2009), therefore, when a patient smokes a cigarette while 
taking varenicline, the effect of nicotine on the brain is limited, hence reducing 
the “reward” sensation that people experience while smoking. 
Varenicline has proven to be the most effective smoking cessation therapy 
thus far (Jiménez-Ruiz et al., 2009).  According to Cahill (2009), when compared 
to use of a placebo, smokers more than doubled their chances of remaining 
abstinent at the six month mark following initial therapy.  When compared to NRT 
and bupropion, users of varenicline had approximately a 30% and 50% greater 
chance of success of continued abstinence at the six month mark, respectively 
(Cahill et al., 2009).  With such improvement in cessation rates, it is not 
surprising that varenicline is estimated to have been prescribed to approximately 
3.5 million people in the United States (Moore, Cohen, & Furberg, 2008).   
While the smoking cessation rates among users are impressive, there 
have been some recent concerns regarding the safety of varenicline.  The FDA 
provides the general public and medical personnel an avenue for reporting 
adverse drug events and reactions on a voluntary basis, known as the Adverse 
Event Reporting System (AERS).   By November 27, 2007, 153 cases of suicidal 
adverse events had been reported via the AERS (U.S. Food and Drug 
Administration, 2009).  These events included 116 cases of suicidal ideation, and 
37 cases of suicide.   Because of the possible correlation of varenicline and 
suicide, the FDA published a formal Public Health Advisory in February, 2008 
(Moore et al., 2008).  The FDA then added a black box warning to varenicline in 
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July, 2009, advising patients and providers of the possible link between 
varenicline and suicidal ideation and/or behaviors (U.S Department of Health & 
Human Services, 2009).   The addition of the black box warning to varenicline 
has lead to several studies to investigate whether or not there is a causal 
relationship.  It has been observed that smokers have a 2-4 times greater risk of 
suicide compared to non-smokers, based on addictive personality types (Miller, 
2000).  And due to withdrawal symptoms, which include depressed mood, it is 
difficult to make a direct causal relationship between the use of varenicline and 
suicidal events.  These health and safety concerns have lead to this relationship 
being evaluated in several studies. 
Purpose of the Study 
The use of varenicline for smoking cessation has been associated with a 
possible increased risk for suicidal ideations and behaviors in recent years.  The 
purpose of this systematic review is to examine the correlation between the use 
of varenicline and this risk of suicide, and to determine if the risks of suicidal 
adverse events outweigh the benefit of smoking cessation.  The outcomes will be 
evaluated using the Grading of Recommendations Assessment, Development, 
and Evaluation (GRADE), which is method used to determine the quality of the 
evidence (see Table 1) (Guyatt et al., 2008). 
METHOD 
 
 An extensive literature search was performed using MEDLINE, Web of 
Science, PubMed, CINAHL, Evidence-Based Medicine Reviews Multifile, 
PsycINFO, and International Pharmaceutical Abstracts.  All databases were 
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accessed through the Pacific University Library system. A search was performed 
using the keyword “Varenicline” in each database, resulting in a total of 1,888 
articles.  The keyword “suicide” was then combined with “Varenicline”, which 
resulted in 71 articles.  Another search was performed combining the terms 
“Varenicline” and “depression”, which yielded an additional 114 articles.   There 
was significant overlap between articles retrieved from the multiple databases.  
Articles were then limited to the English language and human subjects.  
Traditional reviews and individual case studies were excluded from the results.   
The remaining 15 articles were reviewed for content and included if they 
contained information on suicide, suicidal ideation, or suicidal behaviors as a 
primary outcome.  Four articles met the above stated criteria, and were included 
in this systematic review. 
RESULTS  
 A total of four studies were included for review based on the content, on 
the study design, and on the use of suicidal ideation or behaviors as a measured 
outcome.  One randomized control trial, two cohort studies, and one open-label 
trial were reviewed. 
Rigotti et al. 
In 2010, Rigotti et al. performed a randomized, double blinded control trial 
to determine whether using varenicline in patients with stable cardiovascular 
disease (CVD) was a safe and effective means smoking cessation.  The trial 
enrolled 714 current smokers, all of whom had stable CVD for at least two 
months, and all of whom had not attempted to stop smoking within the past three 
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months.  The participants enrolled were between 35 and 75 years old, were 
predominantly male, and were from various locations (15 countries were 
included).   Excluded were patients with a diagnosis of depression, a “history of 
psychosis, panic disorder, or bipolar disorder”, or those who had received 
antidepressant medications within the last year.  The participants were randomly 
assigned to receive the placebo or varenicline for 12 weeks.  The study 
participants were divided into two groups; 353 participants received varenicline 
and 350 participants received a placebo, and both groups received smoking 
cessation counseling. 
While the primary outcomes of the study measured continued abstinence 
rates (CAR) and cardiovascular events, because of the recent concern regarding 
a correlation between varenicline and suicide, the study also measured 
“treatment-emergent adverse events”, which looked at suicidal behaviors and 
depressed mood, along with other adverse events (AE) (Rigotti et al., 2010, p. 
226). 
The study found that 11 participants (3.1%) in the treatment group and 8 
participants (2.3%) in the placebo group experienced a “depressed mood 
disorder or disturbance” either during treatment or within the 52 week follow up 
period.   Additionally, 9 participants in the treatment group (2.5%) and 3 in the 
placebo (0.9%) experienced an “other mood disorder”, which includes dysphoria, 
mood alterations or swings, and/or an emotional disorder.  Neither the treatment 
nor the placebo group had any reports of suicidal behaviors over the treatment 
and follow up period.    The authors concluded that varenicline appears to be 
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safe for use in people with CVD.  They also felt that while it did not cause an 
increased risk of psychiatric events in their study population, further studies 
should be conducted in order to make a definitive assessment of these risks. 
Gunnell et. al. 
A cohort study, performed in 2009 by Gunnell, D. et al., attempted to 
examine the association of suicide and varenicline by comparing smoking 
cessation pharmacotherapy (either varenicline or bupropion) with NRT.  The 
study identified participants through the UK General Practice Research Database 
(GPRD).  Eligible participants were 18 or older and prescribed a new course of 
varenicline, bupropion, or NRT between 9/1/2006-5/31/2008.  The study 
identified 80,660 eligible participants, of whom 10,973 received varenicline, 6,422 
received bupropion, and 63,265 received NRT.  All participants were from 
general practices located throughout the United Kingdom.  Participants were 
entered into the cohort on the date the prescription was written and followed 
through the treatment period, and then for an additional three months.  Electronic 
medical records were obtained for participants during both the treatment and 
follow-up period. 
Outcomes measured in this study included “fatal and non-fatal self harm, 
suicidal thoughts”, and depression, which was measured as being the initiation of 
an antidepressant therapy over the treatment or follow-up periods.  Suicides 
were identified through the GPRD system via medical codes.  Death certificates 
for the suicides were not obtained. 
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The characteristics of the exposure groups were similar, with a few 
notable exceptions.  There was a higher percentage of people with previous 
mental health consultations in the NRT (4.1%) compared to the both the 
bupropion (2.4%) and varenicline (2.5%) groups.  Also, alcohol misuse was 
slightly higher in the NRT compared to bupropion and varenicline (10.6% vs 
7.3% vs 8.3%).  Additionally, current use of antidepressants, hypnotics, and 
antipsychotics were all slightly higher in the NRT groups compared to the 
pharmacotherapy groups.    The previous smoking cessation attempt rates were 
also slightly lower in the NRT group when compared to the other two.  Males had 
a slightly higher incidence of receiving pharmacotherapy compared to NRT. 
The baseline used for comparison of outcomes was NRT.  Over the 
course of the study, there were two cases of fatal suicides, and both occurred in 
the NRT group.  There were a total 166 cases of non-fatal self-harm incidences 
reported, with 9 in the bupropion group and 18 in the varenicline group.  The 
hazards ratio for both varenicline and bupropion suggests a decreased rate of 
self harm, but when they were adjusted for possible confounding factors, there 
was a slightly increased risk.  The confounding factors that appeared to have the 
greatest effect on the hazards ratio were past and current antidepressant usage.  
The adjusted hazards ratio for varenicline compared to NRT was 1.12 (with a 
confidence interval (CI) of 0.67-1.88).  This suggests only a slightly elevated risk 
of 12% when using varenicline compared versus NRT.  The hazards ratio for 
bupropion was similar at 1.17 (CI of 0.59-2.32).   
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There is an increased risk of suicidal thoughts with varenicline and 
bupropion use compared to NRT, with an adjusted hazards ratio of 1.43 (CI 0.53-
3.85) and 1.20 (0.28-5.12).  Therefore there is a 43% greater risk of suicidal 
thoughts with varenicline as compared to NRT. 
  Both the varenicline and bupropion groups were at a decreased risk of 
being started on a new antidepressant medication when compared to NRT.  The 
adjusted hazards ratio for varenicline was 0.88 (CI of .77-1.00) and for bupropion 
was 0.91 (CI of 0.77-1.07).  Therefore, the study concluded that the usage of 
varenicline is not associated any major risks for depression.  
Kasliwai et al. 
The second cohort study, conducted by Kasliwai R. et al. (2009), 
attempted to determine whether or not varenicline is associated with an 
increased suicide risk.  In addition to the primary outcome, the authors also 
looked at adverse psychiatric events.  There is no comparison or placebo used. 
The cohort study is not yet completed, and this article aimed to present the 
interim results of an ongoing study. 
The study design was an observational cohort, but used a “modified 
prescription event monitoring methodology.”  The Drug Safety Research Unit 
(DSRU) identified participants who were prescribed varenicline by a general 
practitioner (GP) after December 2006.  Then a detailed questionnaire was 
mailed to the patient’s GP, approximately four months following the initial 
prescription.  The questionnaire contained questions regarding the patient’s 
demographics, medical history, smoking history, dates of treatment, “clinical 
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event data (obtained during treatment and 1 month after stopping varenicline)”, 
and dosage.  Patient’s names were excluded, and the patients were identified by 
a number.  The GP was also asked to indicate if they suspected any adverse 
events related to the drug.  The GP was asked to fill out the questionnaire, and 
return it.   
Thus far, 2,682 studies have been processed and included.  Studies that 
were not completely filled out were excluded.  The participants were 
predominantly female (at 60.7%), middle aged, and smoked between 11 to 20 
cigarettes daily.  Over half the participants had previously attempted to quit. 
According to the study, there were four cases of attempted suicide and 
two cases of suicidal ideation.  Two of the suicide attempts took place while the 
patients were still taking the medication, and the other four events took place 
after treatment had stopped. None of the attempts were fatal.  All four of the 
patients that attempted suicide had a history of depression, and one had a 
history of alcohol dependence.  All four of the attempts also had some sort of 
precipitating stressor before the attempt.  In the two cases of suicidal ideation, 
one of the patients had a history of depression.  The other had an issue with 
recent life stress. 
The questionnaire also addressed the issue of depression and other 
psychiatric events.  According to the study, 29 patients (approximately 1.1% of 
the study) had disclosed depression as an adverse event.  Additionally, 17 
participants (0.6% of the study) reported a mood change or emotional 
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disturbance.  The most reported psychiatric events were sleep disturbances and 
anxiety.   
The authors of the study choose not to make any definitive conclusions, 
since the results of the study would continue to change as more and more 
responses are received.  They felt that, in the meantime, caution should be used 
when prescribing varenicline to patients with any existing psychiatric illnesses. 
Philip et al. 
The fourth study included in this review was conducted by Philip, N. et al. 
(2009).  The purpose of this open-label study was to determine whether 
treatment with varenicline in smokers with diagnosed depression, who were 
currently taking antidepressants with limited response, would decrease 
depressive symptoms.   The total study period was eight weeks in duration.  
Participants of the study were identified through outpatient clinics at a psychiatric 
hospital.  Eligibility criteria included an Axis I diagnosis via the Diagnostic and 
Statistical Manual of Mental Disorders IV (DSM-IV-TR) of a “mood disorder with 
predominating depressive symptoms”, current antidepressant therapy for at least 
6 weeks, “persisting depressive symptoms, defined as a Quick Inventory of 
Depressive Symptomatology-Self Report (QIDS-SR-16) score of greater than 5”, 
and nicotine dependence.  Patients with renal dysfunction, or who are currently 
pregnant or breastfeeding were excluded.  Additionally, patients with a 
varenicline intolerance were not enrolled.  A total of 18 participants enrolled in 
the study, aged 18-65.  Study participants were predominantly female (at 66.7%).  
The current mood medications prescribed were selective serotonin reuptake 
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inhibitors (44.4%), serotonin-norepinephrine reuptake inhibitors (11.1%), mood 
stabilizer (16.7%), and other antidepressants (27.8%).  The average number of 
cigarettes smoked per day was 18.7, although the range was 10-80. 
The primary outcome measured was a decrease in points via the QIDS-
SR.  Patients completed the QIDS-SR at baseline, and repeated it every two 
week at the clinic visit until the end of the follow up period at week eight.  
Additionally, both patients and providers were asked to fill out the Clinical Global 
Impression-Severity of Illness (CGI-S) and the CGI-Improvement (CGI-I) scales 
at each visit. 
Fourteen of the original study participants completed the study, with four 
discontinuing the medication early due to adverse effects, including nausea and 
anxiety.  The average decrease in the QIDS-SR score over the eight week study 
period was 4.7.  Six of the patients achieved remission of their depressive 
symptoms (classified as a QIDS-SR of 5 of less), and eight had notable decrease 
in their scores.  There was no significant change in the patient rated CGI-S 
score, but the provider rated score decreased on average from 3.1 (+/- 1.1) at 
baseline to 2.1 (+/- 1.4) at the study end. 
While suicidal mood and behaviors were not addressed at the beginning 
of the study, “a post hoc analysis was performed to examine the changes on the 
specific core QIDS-SR-16 mood and suicide items”, which are listed as number 5 
and number 12 on the QIDS-SR-16 survey (Philip, Carpenter, Tyrka, Whiteley, & 
Price, 2009).  There was no increase in scores related to suicide, and a notable 
decrease in score related to mood changes, with a baseline score of 1.98 (+/- 
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0.76) to a study end score of 1.22 (+/- 0.65).  The authors concluded that 
varenicline appears to be effective for smokers with depression, but that more 
comprehensive, double-blinded studies would need to be performed to confirm 
these study results. 
DISCUSSION 
 Smoking is a huge world-wide health burden, so effective cessation 
therapies will continue to be researched and developed.  With the advent of 
varenicline, smokers have a new option for cessation therapy, which has proven 
to be more effective than placebo, bupropion, and NRT for long term cessation 
(Cahill, Stead, & Lancaster, 2008).  When compared to placebo, the participants 
taking varenicline had more than twice the chance of successfully quitting at six 
months (Cahill et al., 2008).  But, with the new safety concerns regarding 
suicidality and suicidal behaviors, providers may not be as willing to prescribe it 
as other forms of cessation therapy, regardless of its higher level of efficacy.  
Therefore, determining whether or not varenicline can be safely used in patients 
is an important issue. 
 The discussion regarding the possible correlation between varenicline and 
suicide is fairly new; therefore there are a limited number of studies that address 
the issue directly.   
Rigotti et al. 
In the study performed by Rigotti et al. (2010), the main focus was to 
determine whether varenicline could be used safely in patients with CVD, but it 
also addressed adverse events, including issues of suicide and depression.   It 
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was the only randomized controlled trial included in this review.   The limitations 
of the study included the exclusion of patients with a diagnosis of depression, 
and those who had taken any antidepressants within past year, which would tend 
to distort the results relevant to mental health issues.   The methods for 
determining the adverse events that occurred to participants during the study 
were not disclosed within the article, which makes it difficult for the reader to 
have confidence in the results.   
The authors did note, that in order make a definitive case that there is not 
a strong correlation between varenicline and suicide, a more “systematic 
assessment” of suicidal symptoms would need to be conducted (Rigotti et al., 
2010, p. 227).  There were no instances of suicidal behaviors within the 714 
participants, and a minimally increased rate of depressed mood and mood 
disturbance.   
The exclusion of participants with depression makes it difficult to 
determine whether varenicline can be used safely in this population, although 
according to the study, patients without depression or other psychiatric illness 
appear to be able to safely take the drug.   
Gunnell et al. 
The main purpose of the study conducted by Gunnell et al. (2009) was to 
determine whether there was an increased risk of suicidal behaviors and 
ideation.  This was the largest study included in this review, and was the only 
study that used NRT as a comparison.   The authors noted that the power of the 
study is limited, because when compared to the general population, the rate of 
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suicide for the entire cohort was lower than would have been expected.    
Additionally, death certificates were not obtained for all deaths over the study 
period. Therefore, it is possible that some instances of suicide were not included 
in the study. 
Also noteworthy, is the fact that baseline characteristics of the NRT and 
varenicline group differ in several important areas.  A larger percentage of the 
NRT had previously experienced mental health issues.  Additionally, the NRT 
had a higher instance of alcohol misuse and previous mental health 
consultations.  This could indicate a provider preference with use of NRT versus 
pharmacotherapy in these populations.  More reliable statistics could have been 
obtained had the study findings been better balanced at baseline. 
The study suggests a minimal increased risk of both fatal and non-fatal 
self harm when compared to NRT, but this risk is small, and because of a wide 
CI, the risk is imprecise.  The authors say that while the CI is wide, the upper 
limits of the 95% CI approach 2, and therefore a twofold risk increase cannot be 
disregarded.  This risk appears to be small and the risk of suicide with its use is 
minimal.  
The risk of suicidal thoughts when taking varenicline was higher when 
compared to NRT, with a 1.43 hazards ratio, meaning there is a 43% greater risk 
of suicidal ideations on the medication.  But again, this CI for this hazards ratio is 
wide, and imprecise.  Also, there is no information regarding NRT and its 
associated risk of suicidal ideation.  Therefore, because of the limited information 
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within the study, a 43% risk increase may be rather insignificant, if the risk of 
suicidal ideation with use is minimal.  
 The study also addressed the issue of depression.  The study used the 
initiation of antidepressants during follow up in order to decide which participants 
had a new diagnosis of depression.   The authors found a decreased risk of 
initiation of antidepressant therapy when compared to NRT.  But this excludes 
any patients who may have experienced a new onset of depression who did not 
receive antidepressant therapy.  As there are multiple other methods of treatment 
for depression, including counseling and behavior change therapy, the 
measurement of antidepressants therapy may exclude multiple new cases of 
depression. 
There appears to be a small risk of suicidal ideation and behaviors when 
compared to NRT.  Additionally, while there is a possibility of a twofold increased 
risk with varenicline, the general risk of suicide with its use appears to be low, 
when compared to the general population.  This study cannot definitively state 
that there is not a risk of suicide with the use of varenicline, but this risk appears 
to be minimal. 
Kasliwai et al. 
 The study by Kasliwai et at. (2009), looks at the use of varenicline and the 
risk of suicidal behaviors and ideations.  With only four suicide attempts and two 
ideations (less than 1% of the total study), the correlation between suicide and 
varencline appears again to be minimal.  But, this study likewise has some 
limitations.  This interim report reflects a small portion of the study that will 
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ultimately result.  Thus, the authors were not yet able to assess the response 
rate, given that not all the questionnaires have been returned.  Furthermore, as 
this is an ongoing study, the sample size will increase, and the results will likely 
change.   The study included only varenicline prescribed by an actual GP, and 
not by other healthcare practitioners.  Hence, a large portion of the population 
who are taking varenicline may have ignored.  The study also fails to give any 
baseline characteristics of the population, so the reader is unable to determine 
what proportion of the cohort has other psychiatric illnesses or co-morbid 
conditions.   
 The study does use a standardized questionnaire for GPs to fill out based 
patient reports.  The questionnaire is detailed (per the authors), to give a broad 
picture of all the adverse events.  But the overall power of the study is low, due to 
the questionable response rate of the providers. 
Philip et al. 
The aim of the study by Philip et al. (2009) was to determine whether or 
not use of varenicline as an adjunctive therapy to antidepressants, improves 
symptoms in patients with diagnosed depression.  The study used the QIDS-SR-
16 to assess changes in depression symptoms, mood changes, and suicidal 
ideation/behaviors.  The study found no evidence of increased suicide 
ideation/behaviors based on the questionnaire.  The study also reported a slight 
increase in mood score from baseline to study end.  But, this study has several 
severe limitations, which make its findings less reliable.  To begin with, the study 
design was open-label, and therefore bias could be easily introduced, as no 
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blinding or concealment occurred.   Moreover, the study had only 18 participants, 
which limits its power based strictly on the small sample size.  The study period 
was short, and there was no follow up after discontinuation of the medication.  
Furthermore, while the providers did not alter the other antidepressants that the 
patients were taking over the course of the study, they were able to prescribe 
both benzodiazepines for anxiety and trazodone for sleep issues, which could 
have affected the outcomes of the study. Additionally, the study used the QIDS-
SR-16, which is depression score questionnaire, to determine depressive 
symptoms, mood changes, and suicidal ideation/behaviors.  While the 
questionnaire is designed to determine depressive symptoms, there is only one 
question that addresses suicide head on.  Due to the limited number of questions 
addressing this specific outcome, and because the suicide analysis was done 
after the study had been completed, this study is of limited value for determining 
whether there is a risk of suicide while taking varenicline. 
Conclusions 
 Only two of the studies included in this review were to address the issues 
of varenicline and suicidal behaviors and ideation, but one of the two was not 
completed.  The other two studies chose to address and analyze the issues of 
suicide only after the study had been completed, so those outcomes were not 
introduced until after the studies had been designed.   Both the Gunnell et al. 
(2009) and the Rigotti et al. (2010) studies included comparisons (NRT and 
placebo), while the other two studies had no controls.    
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 As mentioned earlier in this review, the GRADE method was used to 
review the quality of the evidence and outcomes within each study.  The 
outcomes specifically addressed in this literature review were suicide attempts 
and/or behaviors, suicidal ideation, and depression.   
 The outcome for suicidal attempts and/or behaviors was included in three 
of studies, and two of the studies were downgraded.  The study conducted by 
Kasliwal et al. (2009), had a starting GRADE of low evidence with no changes.  
The Gunnell et al. (2009) study, which also started at a low GRADE, was 
decreased to very low due to the lack of precision in regards to the confidence 
interval, since it was wide and crossed one.  The study conducted by Rigotti et al. 
(2010) was also downgraded in several areas.  The study started at a high 
GRADE because it was a RCT, but it was lowered one level within the study 
quality category due to the lack of disclosure on how suicidal attempts and/or 
behaviors were determined in the study participants. Furthermore, the study was 
downgraded again in the precision category due to the lack of suicidal events, 
which resulted in a low GRADE of evidence.   Overall, combining the studies, the 
suicidal attempts and/or behaviors outcome received a low GRADE for the 
quality of the evidence. 
 The second outcome reviewed was suicidal ideation, which was also 
addressed within three of the studies.  Again, the study conducted by Kasliwal et 
al. (2009), had a starting GRADE of low evidence with no changes.    The 
Gunnell et al. (2009) study was given an initial a low GRADE and downgraded to 
very low, due to the lack of precision around the confidence interval.  The study, 
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conducted by Philip et al, (2009), began with a very low GRADE, and while there 
were deductions for directness and precision, the study was already at the lowest 
level of evidence.  On combination of the studies, the final GRADE for the 
outcome of suicidal ideation was again very low. 
 The last outcome included in the GRADE analysis was depression, and 
was it addressed by Gunnell et al. (2009), Rigotti et al. (2010), and Philip et al. 
(2009).  The Gunnell et al. (2009) study GRADE did not change, and its final 
GRADE level was low.  The Rigotti et al. (2010) study started at a high level of 
evidence, but again due to the lack of disclosure on how depression was 
determined within the study, the study was lowered one level to a moderate 
GRADE.   The last study included by Philip et al. (2009) started at the very low 
GRADE level.  The study would have been lower further in the study quality 
category since there was no blinding, no placebo use, and very few participants.  
Although the study had an increase in one GRADE level due to the large 
magnitude of effect, as over 75% of the participants had decreased depression 
symptoms, the final GRADE remained at the very low level.  Therefore the 
overall GRADE for the depression outcome was low. 
Based on the studies reviewed, the correlation of varenicline use and 
suicide appears minimal.  But, due to the limitations of the studies and the overall 
low GRADE based on the analysis, further studies would likely change this 
conclusion (Guyatt et al., 2008).  Currently, there is insufficient evidence to make 
a definitive decision regarding the safety of the drug, but the studies indicate a 
weak correlation.  That said, varenicline proves to be the most effective form of 
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smoking cessation available to date.  Evidence shows that use of varenicline 
does cause some adverse events including nausea, vomiting, and sleep 
disturbances, so providers need to be aware and warn patients of these possible 
side effects.   And while the there may be a minimally increased risk of suicide 
with its usage, the risk of  eventually dying from smoking related illness for 
smokers is 50%.  Therefore, when balancing these risks, there is a greater risk of 
dying from a smoking related illness with continued smoking compared to the 
unreliable risk of suicidal problems from using varenicline.  Hence, the risks of 
using varenicline for cessation outweigh the risks of continuing to smoke. There 
needs to be further studies conducted on patients who are at an increased risk of 
suicide, mainly those with depression and/or other psychiatric illnesses, to see if 
the use of the drug is safe in these populations.  Until research has been done, 
providers should continue to prescribe its use in these populations with caution.  
But for the general public, it appears to be a safe and effective means of smoking 
cessation. 
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APPENDIX 
GRADE Table – Table 1 
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GRADE of 
Evidence 
for 
Outcome 
Overall 
GRADE 
of 
Evidence 
Base 
Overall 
GRADE 
of 
Evidence 
Base 
Suicidal 
attempts/behaviors 
Varenicline vs None 
1 Cohort  2862 
Very small 
increase Low 0 0 0 0 0 0 0 0 Low 
Low Low 
Varenicline vs NRT 
1 Cohort 80660 
Small increased 
risk Low 0 0 0 -1 0 0 0 0 Very Low 
Varenicline vs 
Placebo 1 RCT 714 No difference High -1 0 0 -1 0 0 0 0 Low 
Suicidal ideations Varenicline vs None 
1 Cohort 2862 
Very small 
increase Low 0 0 0 0 0 0 0 0 Low 
Very 
Low 
Varenicline vs NRT 
1 Cohort 80660 
Small increased 
risk Low 0 0 0 -1 0 0 0 0 Very Low 
Varenicline vs None 1 Open-Label 
study 18 No difference 
Very 
low -2 0 -1 -1 0 0 0 0 Very Low 
Depression Varenicline vs NRT 1 Cohort 80660 Decreased risk Low 0 0 0 0 0 0 0 0 Low Low 
Varenicline vs 
Placebo 1 RCT  714 No difference High -1 0 0 0 0 0 0 0 Moderate 
Varenicline vs None 1 Open-Label 
study 18 Decreased 
Very 
low -2 0 0 0 0 1 0 0 Very Low 
 
